FDA Approves Xpovio Combo for Heavily Treated RRMM Patients
The U.S. Food and Drug Administration (FDA) has approved — with conditions — Xpovio (selinexor) tablets, in combination with the corticosteroid…
News
Scientists Find ‘On/off Switch’ of Malignant MM Cancer Cells, May Lead to New Therapies, Study Says
Scientists discovered a set of genes that work as an “on/off switch” for malignant multiple myeloma cancer cells, which may shed light into new…
FDA Approves Darzalex-Revlimid-dexamethasone Combo to Treat Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved Janssen‘s Darzalex (daratumumab), used in combination with Revlimid…
Empliciti Combo Prolongs Survival in Difficult-to-Treat Multiple Myeloma, New Phase 2 Trial Data Show
Adding Empliciti (elotuzumab) to a regimen including Pomalyst (pomalidomide) and low-dose dexamethasone extended survival and the time without disease progression in patients with relapsed…
Selinexor Combo Yields Strong Responses in Difficult-to-treat Multiple Myeloma
Selinexor in combination with dexamethasone and Pomalyst (pomalidomide) leads to strong and durable anti-cancer responses, without significant side effects, in patients with…
MMRF Launches CureCloud Data Hub to Identify Treatment Targets
Addressing the need for shared, comprehensive data to identify targets and provide personalized treatment road maps, the Multiple Myeloma Research Foundation (MMRF) is…
Darzalex Combo Extends Survival in Newly Diagnosed Myeloma Patients, Phase 3 Trial Shows
Adding Darzalex (daratumumab) to the standard first-line treatment of Revlimid (lenalidomide) plus dexamethasone improves treatment and survival outcomes in multiple myeloma patients…
CT103A CAR T-cell Therapy Leads to Strong Anti-cancer Responses in Relapsed or Refractory Multiple Myeloma Patients, Trial Shows
CT103A, a fully-human anti-B-cell mature antigen (BCMA) CAR T-cell therapy, leads to strong anti-cancer responses in patients with relapsed or refractory multiple…
Ygalo Continues to Induce Clinically Meaningful Responses in Relapsed or Refractory Multiple Myeloma, Phase 1/2 Trials Show
Ygalo (melflufen) combination therapy continues to lead to clinically meaningful responses, without significant side effects, in patients with relapsed or refractory multiple…
Early Data Show Positive Activity of Iberdomide Against Heavily Treated MM
Interim data from an ongoing Phase 1/2 clinical trial show that Celgene’s investigational therapy iberdomide (CC-220), used in combination with dexamethasone, is safe and…
